PACB Earnings

PACB reported its earnings on 2026-02-12, showcasing a revenue of 44.65M against an estimate of 40.40M, resulting in a 10.51% surprise. The EPS was -0.12, surpassing the expected -0.19 by 36.84%. The stock experienced a -7.07% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following PACB's earnings announcement on 2026-02-12, the stock price moved by -7.07% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, PACB's stock price tends to shift by an average of 7.61% in the 10 days leading up to earnings and -7.5% in the 10 days following, providing insight into potential market.

For 2026/Q1, analysts estimate PACB's annual revenue to reach 41.31M, while the EPS is projected at -0.14. These estimates reflect recent revisions, with revenue estimates revised upward by 0.03% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between PACB's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were revised upward by 0.03%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, PACB's stock price typically moves by 7.61% in the 10 days before its earnings and -7.5% in the 10 days after. For the upcoming 2026/Q1 earnings, analysts expect an EPS of -0.14 and revenue of 41.31M.

The earnings call indicates strong product development and market expansion, with optimistic guidance for revenue growth and cost reduction. Despite some uncertainties in management responses, the focus on clinical market penetration, new product launches, and cost-effective sequencing solutions suggests positive sentiment. The Q&A section supports this with expected growth in international markets and operational efficiencies. The positive outlook on revenue and consumable growth, coupled with strategic cost management, outweighs any negative aspects, leading to a positive stock price prediction.